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Abstract
OBJECTIVE: To observe the effect of soothing-liver
and nourishing-heart acupuncture on selective se-
rotonin reuptake inhibitor (SSRIs) treatment effect
onset in patients with depressive disorder and relat-
ed indicators of neuroimmunology.
METHODS: Overall, 126 patients with depressive
disorder were randomly divided into a medicine
and acupuncture-medicine group using a random
number table. Patients were treated for 6 consecu-
tive weeks. The two groups were evaluated by the
Montgomery-Asberg Depression Rating Scale
(MADRS) and Side Effects Rating Scale (SERS) to as-
sess the effect of the soothing-liver and nourish-
ing-heart acupuncture method on early onset of
SSRI treatment effect. Changes in serum 5-hydroxy-
tryptamine (5-HT) and inflammatory cytokines be-
fore and after treatment were recorded and com-
pared between the medicine group and the acu-
puncture-medicine group.
RESULTS: The acupuncture-medicine group had
significantly lower MADRS scores at weeks 1, 2, 4,
and 6 after treatment compared with the medicine
group (P < 0.01). The acupuncture group had signif-
icantly lower SERS scores at weeks 1, 2, 4, and 6 af-
ter treatment compared with the medicine group
(P < 0.01). At 6 weeks after treatment, serum 5-HT
in the acupuncture-medicine group was significant-
ly higher compared with the medicine group (P <
0.01). Interleukin-6 (IL-6) in the acupuncture-medi-
cine group was significantly lower than that in the
medicine group (P < 0.01), whereas there was no
significant difference in IL-1β between the groups
(P > 0.05). Anti-inflammatory cytokines IL-4 and
IL-10 were significantly higher in the acupunc-
ture-medicine group compared with the medicine
group (P < 0.01, P < 0.05, respectively).
CONCLUSION: The soothing-liver and nourish-
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ing-heart acupuncture method can effectively ac-
celerate the onset of SSRI effects when treating de-
pressive disorder and can significantly reduce the
adverse reactions of SSRIs. Moreover, acupuncture
can enhance serum 5-HT and regulate the balance
of pro-inflammatory cytokines and anti-inflamma-
tory cytokines.
© 2015 JTCM. All rights reserved.
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INTRODUCTION
Depressive disorders are a class of mental disease that
have a high prevalence and recurrence rate. According
to epidemiologic data, the prevalence of depressive dis-
order is 10%-20%, and the morbidity ratio of males to
females is 1∶2.1,2 The recurrence rate of depressive dis-
order is 21% in 1 year, and 75% in 10 years.3 Depres-
sive disorder has a high morbidity and relapse rate and
severely affects mentality, social life, work, and study.4
Although there are nonpharmacologic treatments for
depressive disorder, such as psychotherapy and electro-
convulsive therapy, medicine therapy is most common-
ly used and is convenient in the three phases of the dis-
ease: the acute phase, the consolidation period, and the
maintenance period.5 Selective serotonin re-uptake in-
hibitors (SSRIs) are the most widely used fist-line treat-
ments for depressive disorder, and more than 50% of
worldwide antidepressant prescriptions are SSRIs.6,7
However, SSRIs require 4-6 weeks or even more before
treatment effects are obvious.8 This period can lead to
many disadvantages during the treatment course de-
pression, such as symptoms remitting slowly, reduction
in treatment compliance, and increased suicide risk.9
Therefore, accelerating the onset of SSRI effect is very
important for depression treatment.10 We aimed to per-
form a randomized clinical trial to study the effect of
the soothing-liver and nourishing-heart acupuncture
method on the onset of SSRI treatment effect for de-
pression and explore the related neuroimmunology
mechanism.
MATERIALS ANDMETHODS
Study design
The study was a randomized controlled clinical trial.
Patients were randomized using a random number ta-
ble. Patients were unaware of their group allocation.
One hundred twenty-six outpatients were coded from
number 1 to 126. Each coded patient number corre-
sponded to a random number. Those patients with
odd random numbers were allocated to the medicine
group and those with even numbers were allocated to
the acupuncture-medicine group. The study met the
standards of medical ethics and was approved by the
ethics committee of Seventh People's Hospital of Hang-
zhou. All patients signed an informed consent form.
Standards of inclusion
Patients were included if they: (a) met the diagnostic
criteria for major depressive disorder or recurrent de-
pressive disorder according to the International Statisti-
cal Classification of Diseases and Related Health Prob-
lem 10th Revision (ICD-10); (b) scored ≥ 12 points in
the Montgomery-Asberg depression rating scale
(MADRS); (c) were aged 18 to 60 years old; and (d)
had not taken SSRIs within 4 weeks of study inclusion
or stopped taking other antidepressants for more than
4 weeks.
Standards of exclusion
Patients were excluded if they: (a) had physical illness-
es, organic brain diseases, or were dependent on medi-
cations or alcohol; (b) were pregnant or lactating; (c)
had adverse or allergic reactions; or (d) had psychotic
symptoms.
Standards of suspension
Patients were suspended from the study if they: (a)
could not tolerate the acupuncture or SSRI treatment;
(b) had serious adverse reactions during the study; (c)
refused to be treated with acupuncture or SSRIs, or
used other medicines or treatment during the study;
(d) failed to visit; (e) willingly quit the study because of
unexpected conditions; or (f ) had poor obedience with
incomplete data during the study.
Grouping and treatment
Overall, 126 patients with depressive disorder were ran-
domly divided into the medicine group and the acu-
puncture-medicine group. Each group eventually had
60 patients, with 5 patients that dropped out of the
study from the medicine group and 1 patient from the
acupuncture-medicine group.
Medicine group: patients with depressive disorder were
randomly treated with fluoxetine (Lilly Pharmaceutical
Limited Company, Suzhou, China), paroxetine (Glaxo-
SmithKline Pharmaceutical Limited Company, Tian-
jin, China), citalopram (Lundbeck Pharmaceutical
Limited Company, Xian, China), sertraline (Pfizer
Pharmaceutical Limited Company, Dalian, China), or
fluvoxamine (Abbott Pharmaceutical Limited Compa-
ny, Chatillon Sur Chalaronne, France). The starting dose
of fluoxetine, paroxetine, and citalopram was 20 mg/
d, and dose adjustment was 20-60 mg/d. The starting
dose of sertraline was 50 mg/d, and dose adjustment
was 50-200 mg/d. The starting dose of fluvoxamine
was 50 mg/d, and dose adjustment was 50- 300 mg/d.
Medications were administered orally 1-2 times/d, and
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doses were adjusted based on clinical symptoms and
medicine reactions. Treatments were maintained con-
tinuously for 6 weeks.
Acupuncture-medicine group: The pharmaceutical tre-
atment in the acupuncture-medicine group was identi-
cal to that of the medicine group. However, the sooth-
ing-liver and nourishing-heart acupuncture method
was also performed on each patient. The following acu-
points were selected: Taichong (LR 3), Ququan (LR
8), Qimen (LR 14), Danzhong (CV 17), Shuigou (GV
26), Neiguan (PC 6), Shenmen (HT 7), and Xinshu
(BL 15). The selected points were aimed at dispersing
stagnated liver Qi to relieve Qi stagnation and tranquil-
izing by nourishing the heart. The selected acupunc-
ture points were operated by a dedicated doctor of tra-
ditional Chinese medicine. Disposable sterile acupunc-
ture needles of Xinglin brand, 0.30 mm in diameter
and 30 mm or 40 mm in length, were used for acu-
puncture (produced by Tianyuheng Technology Limit-
ed Company, Beijing, China). When needling, slow
piercing, Taichong (LR 3), Ququan (LR 8), Qimen
(LR 14), and Danzhong (CV 17) were operated by the
neutral drainage method; and Shuigou (GV 26), Nei-
guan (PC 6), Shenmen (HT 7), and Xinshu (BL 15)
were operated by the neutral supplementation method.
Needles were retained for 30 min after De Qi. Patients
received one acupuncture treatment every other day for
6 weeks.
Assessment of clinical symptoms
MADRS score: The MADRS score can precisely re-
flect changes in depressive symptoms, especially antide-
pressant effect. The scale includes 10 items, and each
item has 7 levels (0-6 points). Ratings range from 0-60
points, with higher scores indicating more severe de-
pression. The medicine group and the acupunc-
ture-medicine group were assessed before treatment
and at weeks 1, 2, 4, and 6 after treatment.
Side Effects Rating Scale (SERS) score: SERS can clear-
ly evaluate adverse effects of antidepressants. The scale
includes 14 items, and each item has 4 levels (0-3
points). Ratings range from 0-42 points, with higher
scores indicating more severe antidepressant adverse ef-
fects.
The MADRS and SERS scores in each group were ex-
clusively evaluated by an associate chief psychiatrist.
Detection of biological indicators
Serum 5-Hydroxytryptamine (5-HT) and inflammato-
ry cytokines secreted by TH1/TH2: Both groups gave
6-ml fasting venous blood in 2% ethylene diamine tet-
ra-acetic acid anticoagulant tube from 8:00-9:00 AM
before treatment and at 6 weeks after treatment. After
centrifuging at 3200 r/min for 5 min to remove the su-
pernatant, serum was stored at －70 ℃ until use. Se-
rum 5-HT, interleukin-1 beta (IL-1β), IL-6, IL-4, and
IL-10 were detected by enzyme-linked immunosorbent
assay (ELISA) at the Molecular Biology Laboratory of
Seventh People's Hospital of Hangzhou after all the
samples were collected. The 5-HT ELISA Kit was pro-
vided by US Biological Technology Limited Company
(Swampscott, MA, USA). IL-1β, IL-6, IL-4, and
IL-10 ELISA Kits were provided by MultiSciences Bio-
tech Limited Company (Hangzhou, China).
Statistical analysis
SPSS 13.0 software (SPSS China Software Shanghai
Limited Company, Shanghai, China) was used to pro-
cess data in the study. Measurement data are expressed
as mean ± standard deviation ( xˉ ± s). Independent
samples t-test was used to compare measurement data.χ2 test was used to compare enumeration data. P <
0.05 was regarded as a statistical difference.
RESULTS
Patients
Overall, 126 outpatients with depressive disorder were
divided into a medicine group and acupuncture-medi-
cine group from January 2013 to October 2013 in Sev-
enth People's Hospital of Hangzhou. There were 60 pa-
tients in the medicine group, 30 males and 30 females,
aged (37 ± 10) years and depression duration (4 ± 4)
months. There were 60 patients in the acupunc-
ture-medicine group, 29 males and 31 females, aged
(36 ± 10) years and depression duration (4 ± 3)
months. There were no significant differences in sex,
age, or depression duration between the two groups
(P > 0.05) (Figure 1).
MADRS score
There was no significant difference in MADRS score
before treatment between the medicine group and the
acupuncture-medicine group (P > 0.05). Compared
with MADRS scores before treatment, there was signifi-
cant difference in MADRS score at 1, 2, 4, and 6
weeks after treatment in the medicine group (tweek 1 =
4.14, P < 0.01; tweek 2 = 6.03, P < 0.01; tweek 4 = 10.13, P <
0.01; tweek 6 = 14.00, P < 0.01), and there was a signifi-
cant difference in MADRS score at weeks 1, 2, 4, and
6 after treatment in the acupuncture-medicine group
(tweek 1 = 6.99, P < 0.01; tweek 2 = 14.60, P < 0.01; tweek 4=
22.10, P < 0.01; tweek 6 = 27.83, P < 0.01). There was a
significant difference in MADRS score at 1, 2, 4, and 6
weeks after treatment between the two groups (P <
0.01) (Table 1).
SERS score
There was a significant difference in SERS scores at
weeks 1, 2, 4, and 6 after treatment between two
groups (P < 0.01) (Table 2).
Serum 5-HT and inflammatory cytokines
There were no significant differences in serum 5-HT
between two groups before treatment (t = 0.14, P >
0.05). There was a significant difference in serum 5-HT
between the medicine group and the acupuncture-med-
509
JTCM |www. journaltcm. com October 15, 2015 |Volume 35 | Issue 5 |
Liu Y et al. / Clinical Study
icine 6 weeks after treatment (t = −3.78, P < 0.01).
There was no significant difference in IL-1β between the two groups before treatment (t = 0.21, P > 0.05).There was no significant difference in IL-1β between
Time point
Before treatment
1 week
2 week
4 week
6 week
Medicine (n = 60)
26±3
23±3a
21±5a
18±5a
15±5a
Acupuncture-medicine (n = 60)
25±3
22±3bc
18±3bc
14±3bc
11±3bc
t value
0.652
3.784
4.606
5.637
5.739
P value
0.516
0.000
0.000
0.000
0.000
Notes: medicine group: treated with selective serotonin reuptake inhibitor (SSRIs) for 6 weeks, dose adjustment of fluoxetine, paroxetine,
and citalopram 20-60 mg/d, sertraline 50-200 mg/d, fluvoxamine 50-300 mg/d. Acupuncture-medicine group: treated with SSRIs and the
soothing-liver and nourishing-heart acupuncture method for 6 weeks. MADRS: montgomery-asberg depression rating scale. Compared
with MADRS score before treatment, at 1, 2, 4, and 6 weeks after treatment, in the medicine groups, aP < 0.01, in the acupuncture-medi-
cine group, bP < 0.01; compared with MADRS score at 1, 2, 4, and 6 weeks after treatment in the medicine group, at the corresponding
time points in the acupuncture-medicine group, cP < 0.01.
Table 1 Comparison of MADRS scores in patients with depressive disorder before treatment and after treatment between two
groups ( xˉ ± s)
Time point
1 week
2 week
4 week
6 week
Medicine (n = 60)
9.8±2.6
8.9±2.6
7.9±2.6
7.0±2.6
Acupuncture-medicine (n = 60)
7.5±2.9a
5.7±3.0a
3.9±2.7a
2.8±2.4a
t value
4.46
6.14
8.41
9.27
P value
0.000
0.000
0.000
0.000
Notes: medicine group: treated with selective serotonin reuptake inhibitor (SSRIs) for 6 weeks, dose adjustment of fluoxetine, paroxetine,
and citalopram 20-60 mg/d, sertraline 50-200 mg/d, fluvoxamine 50-300 mg/d. Acupuncture-medicine group: treated with SSRIs and the
soothing-liver and nourishing-heart acupuncture method for 6 weeks. 1 week: assessed at 1 week after treatment by SERS score; 2 week: as-
sessed at 2 weeks after treatment by SERS score; 4 weeks: assessed at 4 weeks after treatment by SERS score; 6 weeks: assessed at 6 weeks af-
ter treatment by SERS score. SERS: rating scale for side effects; SSRIs: selective serotonin reuptake inhibitors. Compared with SERS score
of medicine group at 1, 2, 4, and 6 weeks after treatment, at the corresponding time points in the acupuncture-medicine group, aP < 0.01.
Table 2 Comparison of SERS scores in patients with depressive disorder after treatment between two groups ( xˉ ± s)
Evaluated whether entry the study according
to standard of inclusion and exclusion
Randomization
(n = 126)
Medicine group
(n = 65)
Acupuncture-drug
group
(n = 61)
Loss of follow up (n = 1)
Dropout due to adverse reactions (n = 4) Loss of follow up (n = 1)
Analyze inclusion (n = 60)
Analyze the dropout reason
Analyze inclusion
(n = 60)
Figure 1 Study flowchart
Medicine group: treated with selective serotonin reuptake inhibitor (SSRIs) for 6 weeks, dose adjustment of fluoxetine, paroxetine,
and citalopram 20-60 mg/d, sertraline 50-200 mg/d, fluvoxamine 50-300 mg/d. Acupuncture-medicine group: treated with SSRIs
and the soothing-liver and nourishing-heart acupuncture method for 6 weeks.
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the two groups 6 weeks after treatment (t = 0.22, P >
0.05).
There was no significant difference in IL-6 between
the medicine group and the acupuncture–medicine
before treatment (t = 0.46, P > 0.05). There was a sig-
nificant difference in IL-6 between the two groups 6
weeks after treatment (t = 10.12, P < 0.01).
There was no significant difference in IL-4 between
the medicine group and the acupuncture-medicine be-
fore treatment (t = −0.07, P > 0.05). There was a signif-
icant difference in IL-4 between the two groups 6
weeks after treatment (t = −12.79, P < 0.01).
There was no significant difference in IL-10 between
the medicine group and the acupuncture-medicine be-
fore treatment (t = −0.16, P > 0.05). There was a signif-
icant difference in IL-10 between the two groups 6
weeks after treatment (t = −2.30, P < 0.05) (Table 3).
DISCUSSION
Currently, the first-line treatments in Western Medi-
cine for depressive disorder are atypical antidepres-
sants. SSRIs, a class of atypical antidepressants, ac-
count for more than 50% of antidepressant prescrip-
tions worldwide.11 Psychopharmacologically, SSRIs se-
lectively inhibit 5-HT reuptake in the presynaptic neu-
rons, but do not affect norepinephrine or dopamine.
SSRIs have some adverse reactions and have a slow on-
set of treatment effect, which can cause problems in
clinical treatment. Patients may not have relief of de-
pressive symptoms and must bear some adverse reac-
tions, which delays the patients' physiological, psycho-
logical and social recovery time. These problems lead
to prolonged treatment, decreased adherence, and an
increased risk of suicidal behavior.9,12 Given the disad-
vantage of onset delay and adverse reactions, Chinese
medicine in the treatment of depressive disorder has
been increasingly focused, researched, and applied. Spe-
cifically, acupuncture in the treatment of depressive dis-
order has shown some advantages.13
Acupuncture can influence the endogenous synthesis
and metabolism of neuro-endocrine-immune substanc-
es via its mechanical stimulation. This effect can stimu-
late the body's self-healing capabilities.14 Clinical stud-
ies have shown that, apart from the core symptoms of
depression, acupuncture can significantly improve its
accompanying symptoms including anxiety, sleep disor-
ders, appetite disorders, and cognitive impairment. Fur-
thermore, acupuncture shows fewer adverse reactions,
good tolerance, and high compliance. However, acu-
puncture alone cannot adequately improve the core
symptoms of moderate to severe depressive disorder.15,16
Nevertheless, acupuncture combined with antidepres-
sant therapy could mutually enhance their advantages
and complement their disadvantages.17 Clinical studies
have shown that acupuncture combined with antide-
pressant therapy is clinically effective and has fewer ad-
verse reactions. However, most studies involve acupunc-
ture combined with a certain antidepressant, and stud-
ies on acupuncture combined with a class of antidepres-
sant like SSRIs are rarer. Furthermore, the effect of acu-
puncture on the early onset of SSRIs treatment has not
been reported at present.18
In this study, we combined the broad treatment charac-
teristics of acupuncture with the single neurotransmit-
ter target of SSRIs to treat depressive disorder. We
found that acupuncture combined with SSRIs has cer-
tain clinical advantages. After 6 weeks of treatment, the
MADRS score in the acupuncture-medicine group was
lower than that of the medicine group, which indicated
that the soothing-liver and nourishing-heart acupunc-
ture method can effectively accelerate the treatment ef-
fects of SSRIs. After 6 weeks of treatment, the SERS
score in the acupuncture-medicine group was lower
than that of the medicine group, which indicated that
the soothing-liver and nourishing-heart acupuncture
method can significantly decrease the number of SSRI
adverse reactions. Although the sample size was some-
what small, acupuncture could reduce the dropout rate
because of SSRI adverse reactions. Therefore, for the
shortcomings of SSRIs, such as early onset and adverse
reactions, can be ameliorated with the soothing-liver
Table 3 Comparison of serum 5-HT and inflammatory cytokines secreted by TH1/TH2 in patients with depressive disorder before
treatment and 6 weeks after treatment ( xˉ ± s)
Index
5-HT (mmol/L)
IL-1β (pg/mL)
IL-6 (pg/mL)
IL-4 (pg/mL)
IL-10 (pg/mL)
Medicine (n = 60)
Before treatment
17.1±5.7
5.2±0.8
6.9±0.8
2.8±0.6
98.9±17.0
At 6 weeks after treatment
21.0±5.5
4.2±0.8
4.8±0.8
5.8±0.6
111.6±19.9
Acupuncture-medicine (n = 60)
Before treatment
16.9±5.6a
5.2±0.9a
6.8±0.8a
2.8±0.6a
99.3±16.6a
At 6 weeks after treatment
24.9±5.7b
4.2±0.8c
3.3±0.8b
7.3±0.6b
118.9±14.2d
Notes: medicine group: treated with selective serotonin reuptake inhibitor (SSRIs) for 6 weeks, dose adjustment of fluoxetine, paroxetine,
and citalopram 20-60 mg/d, sertraline 50-200 mg/d, fluvoxamine 50-300 mg/d. Acupuncture-medicine group: treated with SSRIs and the
soothing-liver and nourishing-heart acupuncture method for 6 weeks. 5-HT: 5-hydroxytryptamine; IL-1β: interleukin-1 beta; IL-6: inter-
leukin-6; IL-4: interleukin-4; IL-10: interleukin-10; SSRIs: selective serotonin reuptake inhibitors. Compared with the medicine group be-
fore treatment, aP > 0.05; compared with the medicine group 6 weeks after treatment, bP < 0.01, cP > 0.05, and dP < 0.05.
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and nourishing-heart acupuncture method. Moreover,
the soothing-liver and nourishing-heart acupuncture
method combined with SSRIs can increase confidence
and reduce the risk of early suicide in depression.
Although studies have shown that acupuncture can im-
prove many symptoms in depressive disorders, the pat-
tern identification in depressive disorder and typing
and selection of acupuncture points is not uniform.
Many studies have not proposed treatment laws for de-
pressive disorder according to the literature.19 Accord-
ing to a clinical study on pattern identification and typ-
ing of depressive disorder, depressive disorder is mainly
related to the heart and liver, disharmony of the hepat-
ic Qi, restlessness of the cardiac Qi, flaming of the car-
diac fire, phlegm confusing the mind, and disharmony
of channels and their collateral channels. These pat-
terns accounted for 67.7% of the total pattern identifi-
cation and typing of depressive disorder.20,21 Therefore,
the soothing-liver and nourishing-heart method should
be used to treat depressive disorder. Research has
shown that the pathogenesis of depressive disorder is
not because of single neurotransmitter conduction dis-
orders, but neuro-endocrine-immune system disor-
ders.11,22 A number of studies have confirmed that de-
pressive disorder includes neuroimmune dysfunction.
In fact, the "inflammatory response system model of
depression," hypothesizes that depression is related to
the activation of the inflammatory response system,
which is a neuroimmune disorder. The peripheral im-
mune activation occurs via the release of various in-
flammatory cytokines associated with depression caus-
ing neuroendocrine and neurochemical changes and in-
teractions.23,24 Therefore, depressive disorder not only
results in low serum 5-HT but also immune imbalanc-
es, which mainly results in pro-inflammatory and an-
ti-inflammatory cytokine imbalances secreted by TH1/
TH2.25,26 Studies have shown that the proinflammatory
cytokines IL-1β and IL-6 are harmful to controlling de-
pressive symptoms,27 and the anti-inflammatory cyto-
kines IL-4 and IL-10 are beneficial to alleviating de-
pressive symptoms.28 Therefore, depressive disorders
can be caused by the balance of proinflammatory and
anti-inflammatory cytokines.29 Most studies have
shown that acupuncture can improve depression from
the perspective of clinical symptomatology, but fewer
have explored the treatment mechanism of depressive
disorder regarding the neuro-endocrine system in its
acute phase.18 We found that, compared with single SS-
RI treatment, the soothing-liver and nourishing-heart
acupuncture method combined with SSRIs can not on-
ly improve serum 5-HT faster, but also more effective-
ly reduce pro-inflammatory cytokines secreted by TH1
and increase anti-inflammatory cytokines secreted by
TH2. This effect could explain the acceleration of SS-
RI treatment effect.
In conclusion, this study made use of the broad charac-
teristics of acupuncture from Traditional Chinese Med-
icine to regulate the neuroimmune system and the sin-
gle neurotransmitter target SSRIs to treat depressive
disorder. The results showed that the soothing-liver
and nourishing-heart acupuncture method can effec-
tively accelerate the onset of SSRI treatment effects on
depressive disorder and significantly reduce the adverse
reactions of SSRIs. Furthermore, the mechanism of in-
flammatory factors in acupuncture combined with SS-
RIs on depressive disorder was discussed. However,
there are still some points worth further study. First,
this study detected samples of peripheral blood 5-HT,
which may not be fully representative of synaptic gap
5-HT. Second, the effect of acupuncture combined
with other antidepressants has not been studied. Final-
ly, the biological mechanism of depressive disorder in-
volves the neuro-endocrine-immune system, so it re-
mains to be elucidated exactly how acupuncture com-
bined with antidepressants influences other aspects the
body.
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